Linagliptin Parent Nucleus Intermedia CAS 853029-57-9 Puritas ≥99.0% Factory

Description:

Nomen: Linagliptin parens Nucleus intermedius

CAS: 853029-57-9

Puritas: ≥99.0%

Aspectus: Alba et lux Yellow pulveris

Intermedia pro Linagliptin (CAS: 668270-12-0) tractationis genus II diabete mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple Linagliptin et intermedia:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermedia CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl) -3-methylxanthine CAS 666816-98-4
2-(Chloromethyl) -4-Methylquinazoline CAS 109113-72-6
(R) -3-(Boc-Amino) piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0

Chemical Properties:

Nomen chemicum	8-bromo-7-sed-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purinum-2,6-dione
Synonyma	Linagliptin Parent Nucleus;Linagliptin medium F
CAS Number	853029-57-9
CATTUS Number	RF-PI502
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C20H17BrN6O2
M. Pondus	453.29
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad lux Yellow pulveris
Lepidium sativum	IR/HPLC
Puritas	≥99.0%
Aquae (KF)	≤1.0%
Residere in Ignition	≤0.50%
Totalis immunditias	≤1.0%
Test Standard	Enterprise Standard
Consuetudinem	Intermedia pro Linagliptin (CAS: 668270-12-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

8-bromo-7-sed-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purinum-2,6-dione(CAS: 853029-57- 9) nucleus parentis Linagliptin est (CAS: 668270-12-0).Linagliptin (nomina Tradjenta et Trajetna) inhibitor est dipeptidyli peptidasi-4 (DPP-4), qui ab US FDA mense Maio 2011 probatus est ad tractationem Type 2 diabetae una cum victu et exercitatione.Linagliptin (BI-1356) descriptus est ut potentissimus selectivus, tardus rate et longus agendi inhibitoris DPP-4.Linagliptin ortum est ex optimizatione nisus xanthine-substructio DPP-4 inhibitores cum plumbo initiali ab expeditione HTS notati.